Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
JUNE | |||
Collegium Pharmaceutical Inc.* | Lupin Ltd. (India; Bombay: LUPIN) | Agreement for Collegium to sell Lupin all worldwide rights to AllerNaze nasal spray for nasal symptoms associated with both seasonal allergic rhinitis and perennial allergic rhinitis in adults and children | Financial terms were not disclosed (6/30) |
EpiCept Corp. (EPCT) | IDIS* (UK) | Agreement to administer a named patient program for Ceplene, which is approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia | Ceplene is now available in advance of its commercial launch later this year (6/2) |
Immuno-Cellular Therapeutics Ltd. (OTC BB:IMUC) | Formatech Inc.* | Agreement for the manufacture of IMUC's cancer stem cell vaccine candidate, ICT-121, for an upcoming Phase I trial | The study will target glioblastoma; financial terms were not disclosed (6/24) |
MediGene AG (Germany; FSE:MDG) | Juste SAQF* (Spain) | Marketing partnership for the commercialization of Veregen ointment in Spain and Portugal | Juste will promote and distribute the drug for the treatment of genital warts; MediGene could receive $3.58M in payments plus royalties (6/23) |
Nuvo Research Inc. (Canada; TSX: NRI) | Covidien Inc. (NYSE:COV) | Agreement to commercialize Pennsaid for osteoarthritic knee pain | Covidien is paying Nuvo $10M up front and $15M more if the lotion wins FDA clearance, an amount that could increase to $20M if the agency agrees to certain labeling criteria (6/16) |
Penwest Pharmaceuticals Co. (PPCO) and Endo Pharmaceuticals Holdings Inc. (ENDP) | Valeant Pharmaceuticals International (NYSE:VRX) | Exclusive license allowing Valeant to market Opana ER in Canada, Australia and New Zealand | Valeant agreed to pay C$2M (US$1.8M) up front, plus payments totaling up to C$1M when certain sales milestones are reached in Canada and up to A$1.1M (US$881,402) when certain regulatory and sales milestones are met in Australia (6/9) |
Vivalis (France; Paris:VLS) | Unnamed company | Agreement to produce monoclonal antibodies on its EB66 cell line platform, derived from duck embryonic stem cells | Vivalis has signed seven new commercial licenses since January (6/30) |
JULY | |||
Horizon Discovery Ltd.* | SuperGen Inc. (SUPG) | Commercial agreement relating to its X-MAN technology | It covers the screening of lead compounds on a wide panel of human isogenic cell lines comprising target genotypes of interest to SuperGen (7/15) |
Kineta Inc.* | Airmid Inc.* | Agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid | The array of compounds holds potential for the treatment of multiple sclerosis (7/7) |
Medarex Inc. (MEDX) | Lonza Group Ltd. (Switzerland; LSE: LNA) | Manufacturing agreement for Medarex's pipeline of therapeutic proteins and antibody-drug conjugates | Financial terms were not disclosed (7/9) |
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market.FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | |||